BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kotyla PJ, Engelmann M, Giemza-Stokłosa J, Wnuk B, Islam MA. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? Int J Mol Sci 2021;22:2449. [PMID: 33671049 DOI: 10.3390/ijms22052449] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Gouverneur A, Avouac J, Prati C, Cracowski J, Schaeverbeke T, Pariente A, Truchetet M. JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study. Eur J Clin Pharmacol 2022. [DOI: 10.1007/s00228-022-03402-2] [Reference Citation Analysis]
2 Omair MA, Alkhelb SA, Ezzat SE, Boudal AM, Bedaiwi MK, Almaghlouth I. Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors. Open Access Rheumatol 2022;14:231-42. [PMID: 36276408 DOI: 10.2147/OARRR.S284757] [Reference Citation Analysis]
3 Kotyla P, Gumkowska-sroka O, Wnuk B, Kotyla K. Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus. Pharmaceuticals 2022;15:936. [DOI: 10.3390/ph15080936] [Reference Citation Analysis]
4 Zeng L, Yang T, Yang K, Yu G, Li J, Xiang W, Chen H. Efficacy and Safety of Curcumin and Curcuma longa Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. Front Immunol 2022;13:891822. [DOI: 10.3389/fimmu.2022.891822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Park S, Joung C, Cheong SH, Ryu HY, Lee GH, Pyo GJ, Kwon M. A Case of Superficial Thrombo-occlusive Vascular Disease in a Patient With Rheumatoid Arthritis. J Rheum Dis 2022;29:187-189. [DOI: 10.4078/jrd.2022.29.3.187] [Reference Citation Analysis]
6 Barbu E, Popescu MR, Popescu AC, Balanescu SM. Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging. Int J Mol Sci 2022;23:963. [PMID: 35055149 DOI: 10.3390/ijms23020963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
7 Grossman M, Adler E. Protein Kinase Inhibitors - Selectivity or Toxicity? Protein Kinases - Promising Targets for Anticancer Drug Research 2021. [DOI: 10.5772/intechopen.98640] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Novelli L, Lubrano E, Venerito V, Perrotta FM, Marando F, Curradi G, Iannone F. Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk. Front Med (Lausanne) 2021;8:737079. [PMID: 34631754 DOI: 10.3389/fmed.2021.737079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mori S, Ogata F, Tsunoda R. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Clin Rheumatol 2021;40:4457-71. [PMID: 34554329 DOI: 10.1007/s10067-021-05911-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
10 Zhou YW, Xie Y, Tang LS, Pu D, Zhu YJ, Liu JY, Ma XL. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Signal Transduct Target Ther 2021;6:317. [PMID: 34446699 DOI: 10.1038/s41392-021-00733-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 28.0] [Reference Citation Analysis]
11 Gallo CG, Fiorino S, Posabella G, Antonacci D, Tropeano A, Pausini E, Pausini C, Guarniero T, Hong W, Giampieri E, Corazza I, Federico L, de Biase D, Zippi M, Zancanaro M. COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us? Cytokine 2021;148:155628. [PMID: 34411989 DOI: 10.1016/j.cyto.2021.155628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Gatti M, Turrini E, Raschi E, Sestili P, Fimognari C. Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals (Basel) 2021;14:738. [PMID: 34451835 DOI: 10.3390/ph14080738] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
13 Tucker JA, Martin MP. Recent Advances in Kinase Drug Discovery Part I: The Editors' Take. Int J Mol Sci 2021;22:7560. [PMID: 34299180 DOI: 10.3390/ijms22147560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Rajasimhan S, Pamuk O, Katz JD. Authors' Reply to Moura et al.: "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk". Drugs Aging 2021;38:539-41. [PMID: 33871805 DOI: 10.1007/s40266-021-00856-4] [Reference Citation Analysis]